Stocktoria
Aura Biosciences, Inc. AURA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-10-29
Aura Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $90.3M | $73.3M | $65.2M | $42.2M | $25.2M |
| Operating income | -$112.8M | -$96.1M | -$85.0M | -$60.3M | -$35.2M |
| Income tax | $108,000 | $112,000 | $137,000 | $0 | $0 |
| Net income | -$106.2M | -$86.9M | -$76.4M | -$58.8M | -$35.3M |
| EPS (diluted) | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-8.95 |
| Operating cash flow | -$84.7M | -$79.8M | -$63.8M | -$54.6M | -$32.4M |
| Free cash flow | -$85.2M | -$81.1M | -$64.6M | -$55.7M | -$34.5M |
| Cash & equivalents | $59.5M | $31.7M | $41.1M | $121.6M | $149.1M |
| Total assets | $169.4M | $182.5M | $255.1M | $223.9M | $160.0M |
| Total liabilities | $32.5M | $30.5M | $29.2M | $28.4M | $7.7M |
| Shareholders' equity | $136.9M | $152.0M | $225.8M | $195.6M | $152.3M |
Source: SEC EDGAR filings · CIK 0001501796 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.